Arie Belldegrun

Arie Belldegrun

Signal active

Co-Founder and Chairman

Bio

Arie Belldegrun is the Co-Founder and Chairman of Bellco Capital, a Co-Chairman at Breakthrough Properties, an Executive Chairman and Co-Founder at Allogene Therapeutics, the Founder, Chairman, President, and CEO of Kite Pharma, and the Chairman and Partner at Two River. He attended Hadassah Medical School and Harvard Medical School.

Location

Los Angeles, California, United States, North America

Social

Primary Organization

Bellco Capital

Bellco Capital

Founded

2003

Investment

15

Lead investment

0

Exits

6

Employees

1-10

Industry

Financial Services

Jobs history

5

Bellco Capital

Co-Founder and Chairman

Invalid date - Current

IconOVir Bio

Board Member

2021 - Current

Chairman Of The Board

2017 - Current

Founding Partner

2017 - Current

Breakthrough Properties

Co Chairman

2018 - Current

Board and Advisor Roles

0

N/A

Invest in regions

Profile Resume

Arie Belldegrun is the Co-Founder and Chairman at Bellco Capital, based in United States, North America. With a background in Financial Services, Arie Belldegrun has a rich history of leadership and innovation. Arie Belldegrun studied MD unknown @ The Hebrew University Hadassah Medical School. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.

Recommendation from your interest

N/A

Norbert Bischofberger

Norbert Bischofberger

Co-Founder

Investment portfolio

Arie Belldegrun has made 2 investments. Their Latest investment was Post-IPO Equity - Arno Therapeutics on Aug 16, 2016

Number of investment

2

Number of exits

3

Personal investment

2

Annouced DateOrganization NameFunding RoundMoney Raised
May 02, 2014
Kite Pharma Kite Pharma
Debt Financing - Kite Pharma
50.0M
Aug 16, 2016
Arno Therapeutics Arno Therapeutics
Post-IPO Equity - Arno Therapeutics
8.0M

Partner investment

3

Annouced DateOrganization NameFunding RoundInvestor NameMoney Raised
Apr 19, 2018-
Series A - Allogene Therapeutics
-411.8M
Apr 15, 2020
ByHeart ByHeart
Series A - ByHeart
ByHeart Bellco Capital
70.0M
May 13, 2024
ByHeart ByHeart
Series C - ByHeart
ByHeart Bellco Capital
95.0M

Exits

2

exit.name Kite Pharma

Kite Pharma

Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneer...

Invest in industries

Recent Activity

There is no recent news or activity for this profile.